UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
Date of Report (Date of earliest event reported): August 5, 2026 |
NewAmsterdam Pharma Company N.V.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
The Netherlands |
001-41562 |
N/A |
(State or Other Jurisdiction
of Incorporation) |
(Commission File Number) |
(IRS Employer
Identification No.) |
|
|
|
|
|
Goomieer 2-35 |
|
Naarden |
|
|
The Netherlands |
|
1411 DC |
(Address of Principal Executive Offices) |
|
(Zip Code) |
|
+31 (0) 35 206 2971 |
|
(Registrant’s Telephone Number, Including Area Code) |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s) |
|
Name of each exchange on which registered
|
Ordinary shares, nominal value €0.12 per share |
|
NAMS |
|
The Nasdaq Stock Market LLC |
Warrants to purchase ordinary shares |
|
NAMSW |
|
The Nasdaq Stock Market LLC |
|
|
☐ |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). |
☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. |
Item 2.02 Results of Operations and Financial Condition.
On August 5, 2026, NewAmsterdam Pharma Company N.V. (the “Company”) issued a press release announcing corporate updates and its financial results for the quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 hereto.
**The information contained in Item 2.02, including Exhibit 99.1, is being “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). Additionally, the information contained in Item 2.02, including Exhibit 99.1, shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act or into any filing or other document pursuant to the Exchange Act, except as otherwise expressly stated in any such filing.
Item 9.01 Financial Statements and Exhibits.
|
|
|
Exhibit No. |
|
Description |
|
|
99.1 |
|
NewAmsterdam Pharma Company N.V. Press Release, dated August 5, 2026 |
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
NewAmsterdam Pharma Company N.V. |
|
|
|
|
Date: |
August 5, 2026 |
By: |
/s/ Ian Somaiya |
|
|
Name: |
Ian Somaiya |
|
|
Title: |
Chief Financial Officer |
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
– Announced positive CHMP opinion recommending marketing authorization for obicetrapib and obicetrapib/ezetimibe –
– PREVAIL interim analysis planned for 4Q2026 with result expected in 1Q2027 –
– Topline data from RUBENS Phase 3 expected by year-end 2026 –
– $678.3 million in cash, cash equivalents and marketable securities at June 30, 2026 –
– Company to host investor day today at 9:00 AM ET in New York City –
Naarden, the Netherlands and Miami, USA; August 5, 2026 – NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced financial results for the quarter ended June 30, 2026 and provided a corporate update.
“During the second quarter, we continued to build momentum across our regulatory, clinical, and scientific priorities,” said Michael Davidson, M.D., Chief Executive Officer of NewAmsterdam Pharma. “Our quarterly update is headlined by the positive opinion for Europe from CHMP, recommending the granting of a marketing authorization for Ubeslo and Evlarco, intended for the treatment of primary hypercholesterolemia or mixed dyslipidemia. Additionally, supportive analyses presented at NLA and AAIC continue to expand the growing body of evidence supporting the potential of obicetrapib across multiple diseases. As we continue to advance our late-stage development program and prepare for several important regulatory and clinical milestones in the months ahead, we remain focused on disciplined execution and look forward to sharing additional updates on our strategy, pipeline, and priorities during today’s Investor Day.”
Clinical Development Updates
NewAmsterdam is developing obicetrapib, an oral, low-dose and once-daily, highly-selective cholesteryl ester transfer protein (“CETP”) inhibitor, as a monotherapy and in fixed-dose combination with ezetimibe, as the preferred LDL-C lowering therapy to be used in patients at risk of CVD for whom existing therapies are not sufficiently effective or well-tolerated.
In July 2026, NewAmsterdam announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (“EMA”) has adopted a positive opinion recommending marketing authorization for obicetrapib 10 mg monotherapy and 10 mg obicetrapib plus 10 mg ezetimibe fixed-dose combination (“FDC”) for patients with primary hypercholesterolemia, both heterozygous familial (“HeFH”) and non-familial or mixed dyslipidemia. A final decision from the European Commission is expected later this year.
In July 2026, NewAmsterdam presented four analyses from its Phase 3 BROADWAY program at the Alzheimer's Association International Conference (AAIC) 2026, further characterizing the potential role of CETP inhibition in the prevention of early Alzheimer’s disease. Highlights include:
•Prespecified analyses from the Phase 3 BROADWAY trial demonstrated statistically significant reductions in plasma p-tau217 versus placebo.
•Additional analyses provided further insights into Alzheimer’s disease biology and potential approaches to optimize future clinical development.
In June 2026, NewAmsterdam presented four analyses at the National Lipid Association (“NLA”) Scientific Sessions further characterizing obicetrapib’s differentiated profile across atherosclerotic cardiovascular disease (“ASCVD”) and heterozygous familial hypercholesterolemia (“HeFH”). The analyses included pooled Phase 3 BROADWAY and BROOKLYN data, real-world evidence from a large U.S. claims database and a cross-class review of contemporary cholesterol-lowering development programs. Highlights included:
•Two real-world analyses using the Komodo Claims and Research Dataset highlighted persistent gaps in LDL-C goal attainment, treatment adherence, and tolerability among high-risk patients receiving high-intensity statins, reinforcing the need for additional well-tolerated LDL-C lowering therapies.
•A pooled mediation analysis of the Phase 3 BROADWAY and BROOKLYN trials found that obicetrapib was observed to reduce major adverse cardiovascular events (“MACE”) by 23%, with reductions in LDL-C and lipoprotein(a) jointly mediating 84.5% of this observed benefits. This analysis further found that the observed MACE benefit was primarily attributable to LDL-C lowering, with Lp(a) as an important additional mediator.
•A cross-class review of contemporary cholesterol-lowering development programs suggest suggested non-CVOT MACE assessments may provide meaningful insight into subsequent cardiovascular outcomes.
NewAmsterdam plans to present additional analyses from the BROOKLYN and BROADWAY studies throughout 2026.
Upcoming Milestones and Ongoing Trials:
Following the successful completion and positive topline results of the Phase 3 BROADWAY, TANDEM, and BROOKLYN trials, NewAmsterdam plans to announce additional clinical data from these trials relating to obicetrapib and the fixed-dose combination (“FDC”) of obicetrapib plus ezetimibe during 2026.
The following Phase 3 trials are currently ongoing:
•PREVAIL Phase 3 trial: PREVAIL is a cardiovascular outcomes trial (“CVOT”) evaluating obicetrapib in patients with a history of ASCVD, whose LDL-C is not adequately controlled despite being on maximally tolerated lipid-lowering therapy. NewAmsterdam completed enrollment of over 9,500 patients in April 2024.
•REMBRANDT Phase 3 trial: The REMBRANDT trial utilizes coronary computed tomography angiography imaging to evaluate the effect of obicetrapib plus ezetimibe FDC on coronary plaque burden. The placebo-controlled, double-blind, randomized, Phase 3 trial is being conducted in adult participants with high-risk ASCVD with evidence of coronary plaque who are not adequately controlled by their maximally tolerated lipid-modifying therapy, with the aim to assess the impact of the obicetrapib 10 mg plus ezetimibe 10 mg FDC daily on lipid-rich coronary plaque and arterial wall inflammation characteristics. In March 2026, the trial completed enrollment of 323 patients.
•RUBENS Phase 3 trial: Initiated in December 2025, the RUBENS trial is evaluating obicetrapib alone or in combination with ezetimibe in patients with type 2 diabetes or metabolic syndrome that require additional lowering of LDL-C despite treatment with available therapy. The trial is expected to enroll approximately 300 patients, with topline data expected by year end 2026.
Additionally, NewAmsterdam expects to initiate a new clinical trial evaluating obicetrapib for the prevention of early Alzheimer’s disease in 2026.
Investor Day
NewAmsterdam will host an Investor Day event for analysts and investors, today, August 5, 2026, beginning at 9:00 a.m. ET in New York City.
A live webcast of the R&D event will be available and those who intend to join virtually can pre-register for the webcast through the link here. The live webcast and supporting presentation materials will be available on the Events section of the Investor Relations page of the NewAmsterdam website at ir.newamsterdampharma.com at the time of the live event. An archived replay will be available on the NewAmsterdam website. Please note advanced registration is required for in-person attendance.
First Quarter Financial Results
•Cash Position: As of June 30, 2026, NewAmsterdam recorded cash, cash equivalents and marketable securities of $678.3 million, compared to $728.9 million as of December 31, 2025. The decrease was primarily driven by cash outflows related to research and development costs as the Company continues development of
obicetrapib and spending on selling, general and administrative expenses to support the Company’s ongoing operations, partially offset by cash inflows from the exercise of options and warrants.
•Revenue: NewAmsterdam recognized $3.7 million in revenue for the quarter ended June 30, 2026, compared to $19.1 million in the same period in 2025. Revenue for the three months ended June 30, 2025 was primarily attributable to the recognition of $16.1 million of revenue related to the second installment of development cost contributions under the license agreement with Menarini. Revenue for the three months ended June 30, 2026 was related to Company's supply agreement with Menarini.
•Research and Development (“R&D”) Expenses: R&D expenses were $41.7 million in the quarter ended June 30, 2026, compared to $27.5 million for the same period in 2025. This increase was primarily due to increases in clinical expenses driven by the initiation of clinical trials and increased costs associated with the progression of ongoing trials, and an increase in personnel expenses. Share-based payment expenses included within R&D expenses totaled $5.9 million in the quarter ended June 30, 2026, compared to $5.1 million in the same period in 2025.
•Selling, General and Administrative (“SG&A”) Expenses: SG&A expenses were $26.9 million in the quarter ended June 30, 2026, compared to $27.3 million for the same period in 2025. This decrease was primarily due to decreases in marketing and communication and intellectual property expenses, partially offset by an increase in personnel expenses. Share-based payment expenses included within SG&A expenses totaled $12.5 million in the quarter ended June 30, 2026, compared to $10.1 million in the same period in 2025.
•Net loss: Net loss for the quarter ended June 30, 2026, was $64.1 million, compared to net loss of $17.4 million for the same period in 2025. The individual components of the change are described above in addition to interest income, a non-cash loss related to changes in the fair value of our derivative warrant liabilities and foreign exchange losses.
About Obicetrapib
Obicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company’s Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company’s Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo. The Company commenced the Phase 3 PREVAIL cardiovascular outcomes trial in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of MACE. The Company completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed-dose combination with ezetimibe, have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company.
About Cardiovascular Disease
Cardiovascular disease remains the leading cause of death globally, despite the availability of lipid-lowering therapies (“LLTs”). By 2050 more than 184 million U.S. adults are expected to be affected by CVD and hypertension, including 27 million with coronary heart disease and 19 million with stroke. In the United States from 2019 through 2022, CVD age-adjusted mortality rates increased by 9%, reversing the trend observed since 2010 and undoing nearly a decade of progress. Despite the availability of high-intensity statins and non-statin LLTs, LDL-C target level attainment remains low, contributing to residual cardiovascular risk, and underscoring a significant clinical need for improved therapeutic regimens. Even with 269 million LLT prescriptions written over the last 12 months, 30 million under-treated US adults are not at their risk-based LDL-C goal, of which 13 million have ASCVD. Less than 1 in 4 patients with ASCVD achieve an LDL-C goal of less than 70 mg/dL and only 10% of very high risk ASCVD patients achieve the goal below 55 mg/dL. In addition to the 30 million under-treated U.S. adults, there are 10 million patients diagnosed with elevated LDL-C who are not taking any LLTs including statins. Beyond LDL-C, additional factors are at play, such as lifestyle choices, tobacco use, and obesity, as well as inflammation, thrombosis, triglyceride levels, elevated Lp(a) levels, and type 2 diabetes.
Alzheimer’s Analysis
In BROADWAY, a pre-specified analysis was designed to assess plasma biomarkers of Alzheimer’s disease (“AD”) in patients enrolled in the BROADWAY trial and evaluated the effects of longer duration of therapy (12 months) with a prespecified ApoE population, based on phenotypic analysis. The analysis included 1,535 patients, including 367 ApoE4 carriers (ApoE3/E4 or ApoE4/E4), whose ApoE status was able to be determined. Because this analysis was based on a subset of patients from BROADWAY (which was designed to evaluate LDL-C reductions in an ASCVD and/or HeFH population), the AD analysis was not controlled for baseline differences between the treatment and placebo populations, but statistical analyses were adjusted for baseline biomarker values and age. The absolute and percent change over 12 months in p-tau217, a key biomarker of AD pathology, were measured among patients with baseline and end of study datapoints above the lower limit of quantitation. Additional outcome measures included NFL, GFAP, p-tau181, and Aβ42/40 ratio absolute and percent change over 12 months. NewAmsterdam observed statistically significant lower absolute changes in p-tau217 compared to placebo over 12 months in both the full analysis set (p=0.002; n= 1,535) and in ApoE4 carriers (p=0.02; n=367) as well as favorable trends in the other AD biomarkers. Although a safety analysis was not performed in the AD analysis population, in BROADWAY obicetrapib was observed to be well-tolerated, with safety results comparable to placebo.
About NewAmsterdam
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient therapy that lowers LDL-C while advancing innovation beyond a single marker to better address cardiovascular risk. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 and are subject to the “safe harbor” provisions created thereunder. All statements that are not historical facts are hereby identified as forwarding-looking statements for this purposes and include, among others, statements relating to: the Company’s intention to conduct the PREVAIL interim analysis and its expectations regarding the timing of the interim analysis and when the result of the interim analysis may be announced; expectations regarding the timing of potential approval decisions from the European Commission for obicetrapib and the FDC of obicetrapib plus ezetimibe; the Company’s expectations for total enrollment figures for and topline data from the RUBENS trial by year-end 2026; the initiation of a new clinical trial evaluating obicetrapib in early Alzheimer’s disease in 2026; the therapeutic potential of the Company’s product candidates; the Company’s other plans regarding and the timing for commencing trials, enrolling patients and completing trials, and the timing and forums for announcing data; expected milestones and anticipated progress toward such milestones; and other statements regarding the Company's future operations, prospects, objectives, strategies and other future events.
The Company may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. These forward-looking statements are based upon management’s current expectations and assumptions. Actual results or events could differ materially and adversely from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various risks, uncertainties and other factors, including, among others: uncertainties and delays regarding the initiation, enrollment and completion of the Company’s clinical trials; uncertainties regarding the result of the PREVAIL interim analysis; uncertainties regarding the outcome of the Company’s clinical trials, and whether such outcomes will be adequate to support regulatory review and approval of its product candidates; whether topline, initial or preliminary results, trends or analyses from a particular clinical trial will be predictive of the final results of that trial and whether results of early clinical trials and analyses will be indicative of the results of later clinical trials and analyses, or whether projections regarding clinical outcomes will reflect actual results in future clinical trials or clinical use of the Company’s product candidates; the potential for varying interpretation of the results of clinical trials and analyses; risks related to the Company’s ability to achieve its business plans, objectives and milestones, including approval of the Company’s product candidates and potential commercialization; challenges inherent to the launch of new drug products, if approved; risks related to the Company’s reliance on third parties; unanticipated costs and expenses impacting the
Company’s cash runway; the Company’s ability to continue to source the raw materials for its product candidates and ensure adequate supply of product for clinical trials and, if approved, commercialization; the impact of competing product candidates on the Company’s business; risks and uncertainties relating to intellectual property and regulatory exclusivities; changes in domestic and foreign business, market, financial, political, and legal conditions; and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, that are described in greater detail in the sections entitled “Risk Factors” in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on February 18, 2026 and in its Quarterly Report on Form 10-Q filed with the SEC on August 5, 2026, as well as in other filings the Company may make with the SEC in the future, which are available at www.sec.gov. Any forward-looking statements contained in this press release speak only as of the date of this press release, and the Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of new information, future events, changed circumstances or otherwise, except as otherwise required by law.
Company Contact
Matthew Philippe
P: 1-917-882-7512
matthew.philippe@newamsterdampharma.com
Media Contact
Real Chemistry on behalf of NewAmsterdam
Christian Edgington
P: 1-513-310-6410
cedgington@realchemistry.com
Investor Contact
Precision AQ on behalf of NewAmsterdam
Austin Murtagh
P: 1-212-698-8696
austin.murtagh@precisionaq.com
NewAmsterdam Pharma Company N.V.
Condensed Consolidated Balance Sheet
(Unaudited)
|
|
|
|
|
|
|
|
|
June 30,
2026 |
|
|
December 31,
2025 |
|
(In thousands of USD) |
|
|
|
|
|
Assets |
|
Current assets: |
|
|
|
|
|
Cash and cash equivalents |
|
424,151 |
|
|
|
490,002 |
|
Prepayments and other receivables |
|
23,996 |
|
|
|
38,138 |
|
Marketable securities, current |
|
209,703 |
|
|
|
146,239 |
|
Restricted cash |
|
1,357 |
|
|
|
1,321 |
|
Total current assets |
|
659,207 |
|
|
|
675,700 |
|
Marketable securities, net of current portion |
|
44,409 |
|
|
|
92,609 |
|
Property, plant and equipment, net |
|
411 |
|
|
|
383 |
|
Operating right of use asset |
|
82 |
|
|
|
185 |
|
Intangible assets |
|
343 |
|
|
|
407 |
|
Total assets |
|
704,452 |
|
|
|
769,284 |
|
Liabilities and Shareholders' Equity |
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
Accounts payable |
|
5,422 |
|
|
|
8,970 |
|
Accrued expenses and other current liabilities |
|
10,277 |
|
|
|
15,422 |
|
Deferred revenue, current |
|
2,797 |
|
|
|
3,987 |
|
Lease liability, current |
|
26 |
|
|
|
136 |
|
Derivative warrant liabilities |
|
54,452 |
|
|
|
57,272 |
|
Total current liabilities |
|
72,974 |
|
|
|
85,787 |
|
Lease liability, net of current portion |
|
56 |
|
|
|
66 |
|
Total liabilities |
|
73,030 |
|
|
|
85,853 |
|
Commitments and contingencies (Note 12) |
|
|
|
|
|
Shareholders' Equity: |
|
|
|
|
|
Ordinary shares, €0.12 par value; 400,000,000 shares authorized; 117,651,697 and 114,399,326 shares issued and outstanding as at June 30, 2026 and December 31, 2025, respectively |
|
14,735 |
|
|
|
14,278 |
|
Additional paid-in capital |
|
1,487,792 |
|
|
|
1,426,750 |
|
Accumulated loss |
|
(874,966 |
) |
|
|
(762,390 |
) |
Accumulated other comprehensive income |
|
3,861 |
|
|
|
4,793 |
|
Total shareholders' equity |
|
631,422 |
|
|
|
683,431 |
|
Total liabilities and shareholders' equity |
|
704,452 |
|
|
|
769,284 |
|
NewAmsterdam Pharma Company N.V.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three months ended June 30, |
|
|
For the six months ended June 30, |
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
(In thousands of USD, except per share amounts) |
|
|
|
|
|
|
|
|
|
|
|
Revenue |
|
3,701 |
|
|
|
19,145 |
|
|
|
6,741 |
|
|
|
22,123 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
Research and development expenses |
|
41,673 |
|
|
|
27,516 |
|
|
|
79,682 |
|
|
|
72,267 |
|
Selling, general and administrative expenses |
|
26,892 |
|
|
|
27,264 |
|
|
|
50,343 |
|
|
|
54,416 |
|
Total operating expenses |
|
68,565 |
|
|
|
54,780 |
|
|
|
130,025 |
|
|
|
126,683 |
|
Operating loss |
|
(64,864 |
) |
|
|
(35,635 |
) |
|
|
(123,284 |
) |
|
|
(104,560 |
) |
Other income (expense): |
|
|
|
|
|
|
|
|
|
|
|
Interest income |
|
5,810 |
|
|
|
7,055 |
|
|
|
11,460 |
|
|
|
14,406 |
|
Fair value change – earnout |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
3,992 |
|
Fair value change – warrants |
|
(4,555 |
) |
|
|
2,590 |
|
|
|
1,387 |
|
|
|
16,352 |
|
Foreign exchange gains/(losses) |
|
(526 |
) |
|
|
8,626 |
|
|
|
(2,139 |
) |
|
|
12,919 |
|
Loss before tax |
|
(64,135 |
) |
|
|
(17,364 |
) |
|
|
(112,576 |
) |
|
|
(56,891 |
) |
Income tax expense |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Loss for the period |
|
(64,135 |
) |
|
|
(17,364 |
) |
|
|
(112,576 |
) |
|
|
(56,891 |
) |
Other comprehensive income/(loss) |
|
|
|
|
|
|
|
|
|
|
|
Unrealized gain/(loss) on available-for-sale securities, net of tax |
|
(360 |
) |
|
|
(107 |
) |
|
|
(932 |
) |
|
|
(140 |
) |
Total comprehensive loss for the period, net of tax |
|
(64,495 |
) |
|
|
(17,471 |
) |
|
|
(113,508 |
) |
|
|
(57,031 |
) |
NewAmsterdam Pharma Company N.V.
Condensed Consolidated Statements of Shareholders' Equity
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(In thousands of USD, except share amounts) |
Shares |
|
|
Amount |
|
|
Additional Paid-In Capital |
|
|
Accumulated Loss |
|
|
Accumulated Other Comprehensive Income |
|
|
Total Shareholders' Equity |
|
Balance at December 31, 2024 |
|
108,064,340 |
|
|
|
13,444 |
|
|
|
1,298,160 |
|
|
|
(558,571 |
) |
|
|
4,467 |
|
|
|
757,500 |
|
Issuance of Earnout Shares |
|
1,743,136 |
|
|
|
226 |
|
|
|
40,581 |
|
|
|
— |
|
|
|
— |
|
|
|
40,807 |
|
Exercise of Pre-Funded Warrants |
|
1,293,938 |
|
|
|
162 |
|
|
|
(162 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
Exercise of warrants |
|
15,942 |
|
|
|
2 |
|
|
|
410 |
|
|
|
— |
|
|
|
— |
|
|
|
412 |
|
Exercise of stock options |
|
909,140 |
|
|
|
116 |
|
|
|
2,875 |
|
|
|
— |
|
|
|
— |
|
|
|
2,991 |
|
Vesting of RSUs |
|
142,795 |
|
|
|
18 |
|
|
|
(18 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
Share-based compensation |
|
— |
|
|
|
— |
|
|
|
15,213 |
|
|
|
— |
|
|
|
— |
|
|
|
15,213 |
|
Total loss and comprehensive loss for the period |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(39,527 |
) |
|
|
(33 |
) |
|
|
(39,560 |
) |
As at March 31, 2025 |
|
112,169,291 |
|
|
|
13,968 |
|
|
|
1,357,059 |
|
|
|
(598,098 |
) |
|
|
4,434 |
|
|
|
777,363 |
|
Exercise of warrants |
|
100 |
|
|
|
— |
|
|
|
2 |
|
|
|
— |
|
|
|
— |
|
|
|
2 |
|
Exercise of stock options |
|
340,317 |
|
|
|
46 |
|
|
|
3,378 |
|
|
|
— |
|
|
|
— |
|
|
|
3,424 |
|
Vesting of RSUs |
|
206 |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|
|
— |
|
Share-based compensation |
|
— |
|
|
|
— |
|
|
|
15,179 |
|
|
|
— |
|
|
|
— |
|
|
|
15,179 |
|
Total loss and comprehensive loss for the period |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(17,364 |
) |
|
|
(107 |
) |
|
|
(17,471 |
) |
As at June 30, 2025 |
|
112,509,914 |
|
|
|
14,014 |
|
|
|
1,375,618 |
|
|
|
(615,462 |
) |
|
|
4,327 |
|
|
|
778,497 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2025 |
|
114,399,326 |
|
|
|
14,278 |
|
|
|
1,426,750 |
|
|
|
(762,390 |
) |
|
|
4,793 |
|
|
|
683,431 |
|
Exercise of warrants |
|
56,619 |
|
|
|
8 |
|
|
|
1,745 |
|
|
|
— |
|
|
|
— |
|
|
|
1,753 |
|
Exercise of stock options |
|
1,971,548 |
|
|
|
278 |
|
|
|
10,771 |
|
|
|
— |
|
|
|
— |
|
|
|
11,049 |
|
Vesting of RSUs |
|
214,163 |
|
|
|
30 |
|
|
|
(30 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
Share-based compensation |
|
— |
|
|
|
— |
|
|
|
18,002 |
|
|
|
— |
|
|
|
— |
|
|
|
18,002 |
|
Total loss and comprehensive loss for the period |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(48,441 |
) |
|
|
(572 |
) |
|
|
(49,013 |
) |
As at March 31, 2026 |
|
116,641,656 |
|
|
|
14,594 |
|
|
|
1,457,238 |
|
|
|
(810,831 |
) |
|
|
4,221 |
|
|
|
665,222 |
|
Exercise of warrants |
|
12,752 |
|
|
|
2 |
|
|
|
476 |
|
|
|
— |
|
|
|
— |
|
|
|
478 |
|
Exercise of stock options |
|
971,668 |
|
|
|
135 |
|
|
|
11,701 |
|
|
|
— |
|
|
|
— |
|
|
|
11,836 |
|
Vesting of RSUs |
|
25,621 |
|
|
|
4 |
|
|
|
(4 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
Share-based compensation |
|
— |
|
|
|
— |
|
|
|
18,381 |
|
|
|
— |
|
|
|
— |
|
|
|
18,381 |
|
Total loss and comprehensive loss for the period |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(64,135 |
) |
|
|
(360 |
) |
|
|
(64,495 |
) |
As at June 30, 2026 |
|
117,651,697 |
|
|
|
14,735 |
|
|
|
1,487,792 |
|
|
|
(874,966 |
) |
|
|
3,861 |
|
|
|
631,422 |
|
NewAmsterdam Pharma Company N.V.
Condensed Consolidated Statements of Cash Flows
(Unaudited)
|
|
|
|
|
|
|
|
|
For the six months ended June 30, |
|
|
2026 |
|
|
2025 |
|
(In thousands of USD) |
|
|
|
|
|
Operating activities: |
|
|
|
|
|
Loss for the period |
|
(112,576 |
) |
|
|
(56,891 |
) |
Non-cash adjustments to reconcile loss for the period to net cash flows: |
|
|
|
|
|
Depreciation and amortization |
|
121 |
|
|
|
97 |
|
Non-cash rent expense |
|
(13 |
) |
|
|
3 |
|
Fair value change - derivative earnout and warrants |
|
(1,387 |
) |
|
|
(20,344 |
) |
Loss on disposal of property, plant and equipment |
|
18 |
|
|
|
— |
|
Foreign exchange (gains)/losses |
|
2,139 |
|
|
|
(12,919 |
) |
Amortization of premium/discount on available-for-sale debt securities |
|
(42 |
) |
|
|
(985 |
) |
Share-based compensation |
|
36,383 |
|
|
|
30,392 |
|
Changes in working capital: |
|
|
|
|
|
Changes in prepayments and other receivables |
|
15,354 |
|
|
|
(5,830 |
) |
Changes in accounts payable |
|
(3,480 |
) |
|
|
1,860 |
|
Changes in accrued expenses and other current liabilities |
|
(5,145 |
) |
|
|
(3,514 |
) |
Changes in deferred revenue |
|
(1,190 |
) |
|
|
(6,008 |
) |
Net cash used in operating activities |
|
(69,818 |
) |
|
|
(74,139 |
) |
Investing activities: |
|
|
|
|
|
Purchase of property, plant and equipment, including internal use software |
|
(118 |
) |
|
|
(104 |
) |
Maturities of marketable securities |
|
97,500 |
|
|
|
37,163 |
|
Purchases of marketable securities |
|
(113,653 |
) |
|
|
(193,340 |
) |
Net cash used in investing activities |
|
(16,271 |
) |
|
|
(156,281 |
) |
Financing activities: |
|
|
|
|
|
Transaction costs on December 2024 issue of Ordinary Shares and Pre-Funded Warrants |
|
— |
|
|
|
(1,586 |
) |
Proceeds from exercise of warrants |
|
798 |
|
|
|
184 |
|
Proceeds from exercise of options |
|
21,308 |
|
|
|
11,346 |
|
Net cash provided by financing activities |
|
22,106 |
|
|
|
9,944 |
|
Net change in cash, cash equivalents and restricted cash |
|
(63,983 |
) |
|
|
(220,476 |
) |
Foreign exchange differences |
|
(1,832 |
) |
|
|
12,597 |
|
Cash, cash equivalents and restricted cash at the beginning of the period |
|
491,323 |
|
|
|
771,743 |
|
Cash, cash equivalents and restricted cash at the end of the period |
|
425,508 |
|
|
|
563,864 |
|
Noncash financing and investing activities |
|
|
|
|
|
Issuance of earnout shares |
|
— |
|
|
|
40,807 |
|
|
|
|
|
|
|
Reconciliation of cash, cash equivalents and restricted cash to the Condensed Consolidated Balance Sheets |
|
|
|
|
|
Cash and cash equivalents |
|
424,151 |
|
|
|
563,864 |
|
Restricted cash |
|
1,357 |
|
|
|
— |
|
|
|
425,508 |
|
|
|
563,864 |
|
